Table 1.
Baseline characteristics of the study populations
| Variable | Category | PLD + Bortezomib | Bortezomib |
|---|---|---|---|
| Age (Years) | n | 142 | 137 |
| Mean (SD) | 63.0 (9.61) | 62.2 (9.27) | |
| Median | 62.0 | 63.0 | |
| Range | (37.0, 85.0) | (40.0, 84.0) | |
| Height (cm) | n | 142 | 137 |
| Mean (SD) | 167.2 (12.31) | 167.3 (10.85) | |
| Median | 169 | 169 | |
| Range | (115, 194) | (142, 189) | |
| Weight (kg) | n | 142 | 137 |
| Mean (SD) | 79.0 (16.97) | 77.2 (15.31) | |
| Median | 76.4 | 76.0 | |
| Range | (44.5, 140) | (46.0, 129) | |
| Body surface area (m2) | n | 142 | 137 |
| Mean (SD) | 1.9 (0.24) | 1.9 (0.23) | |
| Median | 1.9 | 1.9 | |
| Range | (1.4, 2.5) | (1.4, 2.4) | |
| Baseline LVEF (%) | n | 142 | 134 |
| Mean (SD) | 62.6 (7.76) | 66.5 (51.33) | |
| Median | 62.0 | 62.0 | |
| Range | (43.0, 88.0) | (48.0, 651) | |
| Sex (n, %) | Female | 61 (43.0) | 49 (35.8) |
| Male | 81 (57.0) | 88 (64.2) |
cm centimeters, kg kilograms, LVEF left ventricular ejection fraction, m 2 meter squared in body surface area, PLD pegylated liposomal doxorubicin, SD standard deviation